The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study.

Patients with inflammatory bowel disease (IBD) have a high risk of developing extra-intestinal manifestations (EIMs). We aimed to assess the cumulative incidence and clinical course of EIMs in patients treated with Vedolizumab (VDZ) and non-gut selective biologic drugs. In this multicenter observational study, we enrolled 1,182 patients with IBD under biologic treatment in tertiary care centers, collecting the rate of new-onset EIMs and the clinical course of new and pre-existing EIMs since the introduction of the ongoing biologic drug (259 VDZ vs. 923 non-gut selective agents, median time 3 vs. 4 years). Among 1,182 patients with IBD (median age of 46 years; 55% men) on biologics, the overall cumulative incidence of new onset EIMs was 4.1% (49/1,182), in particular 6.6% (17/259) on VDZ vs. 3.5% (32/923) on non-gut selective biologics ( Our study suggests that the type of biologic treatment might affect the risk of developing EIMs, with a slightly higher risk in patients on gut-selective therapies. However, a similar clinical course is observed in the two groups.

Informations de copyright

Copyright © 2022 Ferretti, Monico, Cannatelli, Carmagnola, Lenti, Di Sabatino, Conforti, Pastorelli, Caprioli, Bezzio, Saibeni, Mazza, Vecchi, Maconi and Ardizzone.

Déclaration de conflit d'intérêts

CB received lecture fees from Takeda, AbbVie, and Janssen. SS received lecture fees and was an advisory board member for Takeda and Janssen. LP received Lecture fees from AbbVie, Takeda, Sandoz, and Janssen Pharmaceuticals, and served as a member of the Advisory Board of Fresenius-Kabi. FCa served as a consultant to: Mundipharma, Abbvie, MSD, Takeda, Janssen, Roche, and Celgene and received lecture fees from Abbvie, Ferring, Takeda, Allergy Therapeutics, and Janssen, and unrestricted research grants from Giuliani, Sofar, MSD, Takeda, and Abbvie. GM received lecture fees from Janssen-Cilag, Roche, Gilead, Abbvie, and Alfa-Sigma. SA served as a speaker, consultant, and/or advisory board member for the following organizations: AbbVie, MSD, Takeda, Janssen, Pfizer, Sandoz, and Enthera. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.